Medical News / Reporting from AAAAI Meeting 2020: Follow-Up Viaskin Peanut Patch Data Shows Cross-Contamination Benefit

While cross-contamination remains a major concern for individuals with peanut allergies, a new patch could allow people to consume a trace amount of peanut remnants without fear of a reaction. In an interview with HCPLive®, Todd Green, MD, Vice President of Clinical Development and Medical Affairs at DBV Technologies and author of the "Open-Label Follow-Up of the PEPITES Study (PEOPLE) to Evaluate the Long-Term Efficacy and Safety of Epicutaneous Peanut Immunotherapy in Peanut-Allergic Children," explained how the Viaskin Peanut 250 μg could help eliminate the cross-contamination concern. Source: MDMag. By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization.

read more

Few surgical advances this century have had an impact equal to that of transcatheter aortic valve ... read more
While the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) ... read more
Results of a new study are offering clinicians guidance on optimal timing of menopausal hormone replacement ... read more
The clinical discussion as to whether electronic cigarette devices has already begun. But debate still wages ... read more